{"id":217462,"date":"2019-07-30T15:15:38","date_gmt":"2019-07-30T09:45:38","guid":{"rendered":"https:\/\/www.scconline.com\/blog\/?p=217462"},"modified":"2019-07-30T14:51:35","modified_gmt":"2019-07-30T09:21:35","slug":"pfizer-to-combine-off-patent-drug-business-with-mylan","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","title":{"rendered":"Pfizer to combine off-patent drug business with Mylan"},"content":{"rendered":"<p style=\"text-align: justify;\">As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker.<\/p>\n<p style=\"text-align: justify;\">Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%.<\/p>\n<p style=\"text-align: justify;\"><em>&#8220;Combined company, which will sell Mylan\u2019s EpiPen and Pfizer\u2019s Viagra, will be domiciled in the U.S. The deal will be structured in what\u2019s known as a reverse Morris trust, with Pfizer\u2019s Upjohn business divested and then combined with Mylan.&#8221;<\/em><\/p>\n<p style=\"text-align: justify;\">It has been further reported that, New Pfizer venture will focus on drugs where exclusivity has expired. It will combine generic medicines, often made by different companies than the original drug, with off-patent drugs, which Pfizer used to sell as key brands before their patent protection ended.<\/p>\n<hr \/>\n<p>[Source: CNBC]<\/p>\n<p style=\"text-align: right;\">[Image Credits: Financial Express]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker. Pfizer shareholders would own <\/p>\n","protected":false},"author":8808,"featured_media":217463,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[8051,2],"tags":[36838,36840,36839,36837],"class_list":["post-217462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business_news","category-news","tag-mylan","tag-new-venture","tag-off-patent-drug","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer to combine off-patent drug business with Mylan | SCC Times<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer to combine off-patent drug business with Mylan\" \/>\n<meta property=\"og:description\" content=\"As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker. Pfizer shareholders would own\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-30T09:45:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1330\" \/>\n\t<meta property=\"og:image:height\" content=\"887\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Bhumika Indulia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bhumika Indulia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/\"},\"author\":{\"name\":\"Bhumika Indulia\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/#\\\/schema\\\/person\\\/919ec47cc1b871b362af05740398033a\"},\"headline\":\"Pfizer to combine off-patent drug business with Mylan\",\"datePublished\":\"2019-07-30T09:45:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/\"},\"wordCount\":137,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/pfizer.jpg\",\"keywords\":[\"Mylan\",\"New Venture\",\"Off-Patent Drug\",\"Pfizer\"],\"articleSection\":[\"Business News\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/\",\"url\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/\",\"name\":\"Pfizer to combine off-patent drug business with Mylan | SCC Times\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/pfizer.jpg\",\"datePublished\":\"2019-07-30T09:45:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/#\\\/schema\\\/person\\\/919ec47cc1b871b362af05740398033a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/pfizer.jpg\",\"contentUrl\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/pfizer.jpg\",\"width\":1330,\"height\":887},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/2019\\\/07\\\/30\\\/pfizer-to-combine-off-patent-drug-business-with-mylan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer to combine off-patent drug business with Mylan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/#\\\/schema\\\/person\\\/919ec47cc1b871b362af05740398033a\",\"name\":\"Bhumika Indulia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84c1b51748d0297cf12e5a898eccb7bd3eb5f0ab4ae8e275e2e65c4c83f84740?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84c1b51748d0297cf12e5a898eccb7bd3eb5f0ab4ae8e275e2e65c4c83f84740?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84c1b51748d0297cf12e5a898eccb7bd3eb5f0ab4ae8e275e2e65c4c83f84740?s=96&d=mm&r=g\",\"caption\":\"Bhumika Indulia\"},\"url\":\"https:\\\/\\\/www.scconline.com\\\/blog\\\/post\\\/author\\\/editor_1\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer to combine off-patent drug business with Mylan | SCC Times","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","og_locale":"en_US","og_type":"article","og_title":"Pfizer to combine off-patent drug business with Mylan","og_description":"As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker. Pfizer shareholders would own","og_url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2019-07-30T09:45:38+00:00","og_image":[{"width":1330,"height":887,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","type":"image\/jpeg"}],"author":"Bhumika Indulia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Bhumika Indulia","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#article","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/"},"author":{"name":"Bhumika Indulia","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a"},"headline":"Pfizer to combine off-patent drug business with Mylan","datePublished":"2019-07-30T09:45:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/"},"wordCount":137,"commentCount":0,"image":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","keywords":["Mylan","New Venture","Off-Patent Drug","Pfizer"],"articleSection":["Business News","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","name":"Pfizer to combine off-patent drug business with Mylan | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage"},"image":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","datePublished":"2019-07-30T09:45:38+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a"},"breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","width":1330,"height":887},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Pfizer to combine off-patent drug business with Mylan"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a","name":"Bhumika Indulia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84c1b51748d0297cf12e5a898eccb7bd3eb5f0ab4ae8e275e2e65c4c83f84740?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84c1b51748d0297cf12e5a898eccb7bd3eb5f0ab4ae8e275e2e65c4c83f84740?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84c1b51748d0297cf12e5a898eccb7bd3eb5f0ab4ae8e275e2e65c4c83f84740?s=96&d=mm&r=g","caption":"Bhumika Indulia"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/"}]}},"jetpack_featured_media_url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/217462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/8808"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=217462"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/217462\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media\/217463"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=217462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=217462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=217462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}